The Galien Foundation Debuts 2018 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Medical Technology" Categories
NEW YORK, July 26, 2018 /PRNewswire/ -- The Galien Foundation today announced the 2018 Annual Prix Galien USA Award nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and medical technology product achievement that improves the human condition.
To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate tremendous potential to impact human health. Sales data are not considered by the nominating committee in their award nominee selection; only science and health impact.
"The 2018 nominees exemplify breakthroughs in treatment and care that, in many cases, give patients with disabling, debilitating, and deadly diseases hope for the first time," said Dr. Sue Desmond-Hellmann, chair of the Prix Galien USA Awards Committee and CEO of the Bill & Melinda Gates Foundation. "Among these exciting discoveries are products that mobilize a patient's own immune system to fight cancer, and new drugs and devices that deliver more accurate diagnoses and make it easier for patients to complete their treatments. These achievements underpin the mission of the Galien Foundation to improve the human condition."
The Prix Galien USA 2018 nominees include products evaluated in the following categories: "Best Biotechnology Product" - 13 nominees; "Best Pharmaceutical Agent" - 20 nominees; and "Best Medical Technology" - 10 nominees.
Best Biotechnology Product (Nominees)
Alexion Pharmaceuticals, Inc. Strensiq
----------------------------- --------
Alexion Pharmaceuticals, Inc. Kanuma
----------------------------- ------
Boehringer Ingelheim Pharmaceuticals, Inc. Praxbind
------------------------------------------ --------
Genentech & Roche Hemlibra
----------------- --------
Gilead Sciences Yescarta
--------------- --------
GlaxoSmithKline Shingrix
--------------- --------
Janssen Research & Development Tremfya
------------------------------ -------
Merck & Co., Inc. Zinplava
----------------- --------
Novartis Pharmaceuticals Corporation Kymriah
------------------------------------ -------
Pfizer Trumemba
------ --------
Regeneron Pharmaceuticals, Inc. & Sanofi Dupixent
---------------------------------------- --------
Spark Therapeutics Luxturna
------------------ --------
Ultragenyx Pharmaceutical Mepsevii
------------------------- --------
Best Pharmaceutical Agent (Nominees)
AbbVie Mavyret
------ -------
Aerie Pharmaceuticals, Inc. Rhopressa(R)
--------------------------- -----------
Boehringer Ingelheim Pharmaceuticals, Inc. Ofev
------------------------------------------ ----
Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance(R)
------------------------------------------ -----------
Bristol Myers Squibb Pharmaceuticals, Inc. Daklinza(TM)
------------------------------------------ -----------
Celgene Idhifa
------- ------
Eli Lilly and Company Verzenio
--------------------- --------
Endoceutics, Inc Intrarosa(TM)
---------------- ------------
Janssen Biotech, Inc. Invega Trinza
--------------------- -------------
Janssen Research & Development, LLC Darzalex
----------------------------------- --------
Melinta Therapeutics, Inc. VABOMERE
-------------------------- --------
Merck & Co., Inc. Steglatro
----------------- ---------
Merck & Co., Inc. Prevymis
----------------- --------
Mitsubishi Tanabe Pharma America Radicava
-------------------------------- --------
Neurocrine Biosciences Ingrezza
---------------------- --------
Novartis Pharmaceuticals Corporation Rydapt
------------------------------------ ------
Pfizer Inc. & Astellas Xtandi
---------------------- ------
Portola Pharmaceuticals Bevyxxa
----------------------- -------
TESARO, Inc Zejula
----------- ------
Teva Pharmaceutical Industries Ltd. Austedo(R)
----------------------------------- ---------
Best Medical Technology (Nominees)
Abbott Diabetes Care FreeStyle Libre - Flash Glucose Monitoring System
-------------------- -------------------------------------------------
Boston Scientific Corporation AXIOS(TM) - Stent and Electrocautery Enhanced Delivery System
----------------------------- -------------------------------------------------------------
Boston Scientific Corporation SpyGlass
----------------------------- --------
Boston Scientific Corporation Watchman
----------------------------- --------
Brainscope Company, Inc. BrainScope(R) One
------------------------ -----------------
Foundation Medicine, Inc. FoundationOneCDx
------------------------- ----------------
Integra LifeSciences Corporation, Inc. Omnigraft(R) Dermal Regeneration Matrix
-------------------------------------- ---------------------------------------
Koning Corporation, Inc KBCT 1000
----------------------- ---------
Medtronic Implantable System for Remodulin
--------- --------------------------------
Otsuka America Pharmaceutical Inc. Abilify MyCite
(OAPI), Otsuka Pharmaceutical
Development and Commercialization,
Inc. (OPDC) and Proteus Digital Health
--------------------------------------
"The nominees selected by our independent committee of distinguished researchers and academics exemplify a brighter future for all patients, worldwide," said Bruno Cohen, Chairman of the Galien Foundation. "Benchmark science is delivering results that will filter through the entire health enterprise, improving efficiency, enhancing quality, and delivering better outcomes in the real world clinical setting. It's both timely and proper that we gather on October 25th to celebrate the achievements of these researchers and innovators, whose work represents the next chapter of human progress in fighting disease."
The Prix Galien USA Committee is composed of twelve renowned leaders from the biomedical industry and academia, including four Nobel Laureates, responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 25, 2018, at the American Museum of Natural History in New York City. Registration to attend the 2018 Prix Galien USA Awards Ceremony can be accessed here.
Prix Galien Awards Committee 2018
Pr. Susan DESMOND-HELLMANN,
M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA
Committee Chair
Pr. Richard AXEL,
M.D. Nobel Laureate, Co-director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York
Pr. Michael S. BROWN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX
Pr. Laurie GLIMCHER,
M.D. Chief Executive Officer and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School
Pr. Joseph GOLDSTEIN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX
Pr. Robert S. LANGER,
M.D. David H. Koch Institute Professor at MIT
Pr. Cato T. LAURENCIN,
M.D., Ph.D. University Professor, University of Connecticut, CT
Pr. Paul A. MARKS,
M.D. Laboratory Head of Cell Biology Memorial Sloan Kettering Cancer Center, New-York. President Emeritus, MSKCC
Pr. Michael ROSENBLATT,
M.D. Chief Medical Officer of Flagship Pioneering, Cambridge, MA
Pr. Bengt SAMUELSSON, M.D., Ph.D. Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation
Pr. Marc TESSIER-LAVIGNE,
Ph.D. President, Stanford University, Stanford, CA
Pr. P. Roy VAGELOS,
M.D. Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals, Inc.
Committee Chairman (2012 - 2017)
About the Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
For more information, visit www.galienfoundation.org.
Galien Foundation Media Contact:
Giana Gregga
Finn Partners
312-329-3910
giana.gregga@finnpartners.com
View original content with multimedia:http://www.prnewswire.com/news-releases/the-galien-foundation-debuts-2018-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories-300686964.html
SOURCE The Galien Foundation
